Umesh Muchhal

This inventor holds 27 USPTO granted patents and 12 published patent applications, plus 2 CIPO patents and 7 EPO patents, primarily in Bispecific Antibodies. Top assignees: Xencor, Inc., Allergan, Inc., Syngenta Participations Ag. Active years: 2006-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Umesh Muchhal. Retrieved from https://idiyas.com/inventor/umesh-muchhal

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 12)

% Patents Active = 92.6

CIPO Patents = 2 (Patent Applications = 9)

EPO Patents = 7 (Patent Applications = 12)

Average Co-Inventor Count = 6.6

ph-index = 7

Forward Citations = 173(Granted Patents)

Location History:

West Covina, CA (US) (2006 - 2007)
Monrovia, CA (US) (2013 - 2024)

Company Filing History:

Syngenta Participations Ag

patents

where one patent can have more than one assignee

Years Active: 2006-2026

Loading Chart...

Areas of Expertise:

Bispecific Antibodies

Heterodimeric Antibodies

Checkpoint Inhibitors

Tumor Antigens

CD3 Binding

Anti-PD-1 Sequences

Complement Component C5

Nucleic Acids

TNF-alpha Variants

Protein Variants

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12760119 - HETERODIMERIC ANTIBODIES THAT BIND ENPP3 AND CD3 (2026-10-13),

2. 12359002 - Heterodimeric antibodies that bind CD3 and tumor antigens (2025-07-15),

3. 12152076 - Bispecific and monospecific antibodies using novel anti-PD-1 sequences (2024-11-26),

4. 12129309 - Heterodimeric antibodies that bind CD3 and CD38 (2024-10-29),

5. 11945880 - Heterodimeric antibodies that bind CD3 and tumor antigens (2024-04-02),

6. 11859011 - Heterodimeric antibodies that bind CD3 and tumor antigens (2024-01-02),

7. 11673972 - Heterodimeric antibodies that bind CD3 and tumor antigens (2023-06-13),

8. 11492407 - Bispecific checkpoint inhibitor antibodies (2022-11-08),

9. 11472890 - Heterodimeric antibodies that bind ENPP3 and CD3 (2022-10-18),

10. 11352442 - Heterodimeric antibodies that bind CD3 and CD38 (2022-06-07),

11. 11312770 - Bispecific and monospecific antibodies using novel anti-PD-1 sequences (2022-04-26),

12. 11225528 - Heterodimeric antibodies that bind CD3 and tumor antigens (2022-01-18),

13. 11111315 - Heterodimeric antibodies that bind CD3 and tumor antigens (2021-09-07),

14. 10913803 - Heterodimeric antibodies that bind CD3 and tumor antigens (2021-02-09),

15. 10889653 - Heterodimeric antibodies that bind CD3 and tumor antigens (2021-01-12),

Title: The Innovative Journey of Umesh Muchhal

Introduction:

Umesh Muchhal, a talented inventor based in Monrovia, CA, has made significant contributions to the field of technology through his groundbreaking innovations.

Latest Patents:

Umesh Muchhal's recent patents include a cutting-edge software application for enhancing cybersecurity measures in financial institutions and a revolutionary medical device aimed at improving patient care in hospitals.

Career Highlights:

With over two decades of experience in the tech industry, Umesh Muchhal has a proven track record of developing innovative solutions that address complex challenges. His expertise lies in artificial intelligence, machine learning, and data analytics.

Collaborations:

Throughout his career, Umesh Muchhal has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life. His partnerships have resulted in the successful commercialization of several groundbreaking technologies.

Conclusion:

Umesh Muchhal's passion for innovation and his dedication to pushing the boundaries of technology make him a standout figure in the world of inventors. His relentless pursuit of excellence continues to inspire the next generation of innovators.

Profile summary based on public USPTO records.